Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 237 participants.

Also called NCT02827903

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 237 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02827903
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02827903. Randomized; double masking; primary purpose treatment. Start 2016-01-15 (actual); primary completion 2017-11-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia
Condition
Dyslipidemia
Intervention (Drug)
Metformin + Rosuvastatin
Intervention (Drug)
Metformin + placebo
Intervention (Drug)
placebo + Rosuvastatin
Lead sponsor
Jeil Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02827903
Content hash
d64cc4ee2a28a6ad95933c6d5a95b4296eb84ab7f6be762d270da496ed15ca1b